



## Determination of the absolute configuration of vibsantin F by asymmetric synthesis via $\pi$ -allylpalladium complex

Hiroaki Yuasa, Gouki Makado and Yoshiyasu Fukuyama\*

*Institute of Pharmacognosy, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Tokushima 770-8514, Japan*


Received 12 May 2003; revised 11 June 2003; accepted 20 June 2003

**Abstract**—The absolute configuration of vibsantin F (**1**), one of the simplest 11-membered ring vibsane-type diterpene, was established to be 6*R*, 7*S* and 11*S* by asymmetric synthesis. A diastereomer (**1a**) with a 6*S*, 7*S* and 11*S* configuration was synthesized starting from myrcene by procedures featuring a Sharpless asymmetric epoxidation and a high diastereoselective eleven-membered ring formation between a  $\pi$ -allylpalladium complex and a  $\beta$ -ketoester nucleophile. Subsequent reduction of epoxide in **1a** with  $\text{LiAlH}_4$  gave a diol, which was identical with that derived from vibsantin F.  
© 2003 Elsevier Ltd. All rights reserved.

Vibsane-type diterpenes, vibsanins A–F, were first isolated from the leaves of *Viburnum awabuki* by Kawazu<sup>1</sup> in 1980. Although these diterpenes comprised unprecedented carbon skeletons, the proposed plane structures of them had not been refined on except for vibsantin E for a decade.<sup>2</sup> In 1997, we established the absolute configuration of vibsantin B (**2**) on the basis of the chemical conversion of a seven-membered ring version, vibsantin C, the absolute structure of which was determined by X-ray crystallographic analysis.<sup>3</sup> Since then, we have continued chemical studies on this type of diterpenes occurring in *Viburnum* species. As results, a variety of vibsane-type diterpenes have been isolated, thereby dividing into further three subtypes such as eleven-membered, seven-membered,<sup>4</sup> and rearranged ones.<sup>5</sup> Additionally, many of them show interesting biological activities, e.g. piscicidal, plant growth

inhibitory,<sup>1</sup> and cytotoxic activity.<sup>5</sup> However, no effort on synthesis of vibsane-type diterpenes has been made in spite of novel structures with significant biological activities. Hence, we have initiated stereoselective synthesis of the simplest vibsane-type diterpene, vibsantin F (**1**),<sup>1</sup> the relative and absolute stereochemistry for which has remained unsolved. Vibsantin F (**1**) has three chiral centers which are tentatively assignable as 6*S*, 7*S* and 11*S* (**1a**) or 6*R*, 7*S* and 11*S* (**1b**) according to the 7*R* and 11*S* chirality of vibsantin B (**2**).<sup>3</sup> Our first effort has been directed on asymmetric synthesis of **1a** (Fig. 1).


Our synthetic plan for **1a** is outlined in Figure 2. Commercially available myrcene would be converted to diepoxide **3** by asymmetric epoxidation using a Sharpless method<sup>6</sup> followed by regioselective epoxidation on exomethylene. Diepoxide **3** would be coupled with a



**Figure 1.** Possible structures **1a** and **1b** of vibsantin F (**1**).

**Keywords:** vibsantin F; vibsane-type diterpene; absolute configuration;  $\pi$ -allylpalladium complex.

\* Corresponding author. Tel.: +81 88 622 9611 (ext. 5911); fax: +81 88 655 3051; e-mail: [fukuyama@ph.bunri-u.ac.jp](mailto:fukuyama@ph.bunri-u.ac.jp)




**Figure 2.** Synthetic plan of **1a** via a  $\pi$ -allylpalladium complex.

dianion of methyl acetoacetate<sup>7</sup> to give **4**. Stereoselective macrocyclization via  $\pi$ -allylpalladium complex<sup>8</sup> would be employed for **4**, with expectation that eleven-membered ring formation could be diastereoselectively made to give **5**, which would in turn lead to **1a** after several functionalizations.


The synthesis of **1a** began with the allyl alcohol **6** readily available from myrcene.<sup>9</sup> Asymmetric epoxidation of **6** by Sharpless method<sup>6</sup> provided epoxide **7** in 99% yield with 92% ee, determined by <sup>1</sup>H NMR analysis of the corresponding Mosher ester derivative.<sup>10</sup> Regioselective epoxidation of **7** with *m*-chloroperbenzoic acid gave exclusively diepoxide **3** as a diastereomeric mixture in 91% yield. The displacement of mesylate and tosylate of the primary hydroxyl group in **3** with the dianion of methyl acetoacetate did not proceed at all. Therefore, triflate was used as a more effective leaving group, but it was found to be too liable to be isolated. As a result, large excess (5.0 equiv.) of the dianion of methyl acetoacetate<sup>7</sup> was slowly added at 0°C to in situ prepared triflate of **3** to afford compound

**8** with an acetoacetate unit in 94% yield. Introduction of a 4-methyl-3-pentenyl unit was achieved in 77% yield by using sodium hydride and 15-crown-5 as an additive in DMSO, giving rise to the precursor **4** needed for a subsequent palladium-catalyzed macrocyclization (Scheme 1).


Next, our attention was directed toward palladium-catalyzed macrocyclization of the vinyl epoxide **4** through  $\pi$ -allylpalladium complex.<sup>8</sup> Crucial cyclization of the vinyl epoxide proceeded stereoselectively to afford a sole product **9** in 45% yield when 10 mol% Pd(PPh<sub>3</sub>)<sub>4</sub> was used as the catalyst in THF. Switching the palladium-catalyst did not improve the formation of an eleven-membered ring, but recovered mostly **4**. The macrocyclization of **4** to **9** was examined under a catalytic system of 10 mol% Pd(PPh<sub>3</sub>)<sub>4</sub> in a variety of solvent at 0.01M concentration. As results, the use of DMSO as solvent greatly enhanced this stereoselective cyclization to give rise to **9**<sup>11</sup> in 60% yield. The stereoselective formation of **9** can be explained by assuming that transition states **A** and **B**, as shown in Figure 3,




**Scheme 1.** Reagents and conditions: (a) Ti(OiPr)<sub>4</sub>, L-(+)-DET, TBHP, MS 4 Å, CH<sub>2</sub>Cl<sub>2</sub>, -35°C, 99% (92% ee); (b) *m*CPBA, CH<sub>2</sub>Cl<sub>2</sub>, 0°C, 91%; (c) Tf<sub>2</sub>O, Et<sub>3</sub>N, THF, -78°C, then 5 equiv. the dianion of methyl acetoacetate generated with NaH and *n*BuLi, THF, 0°C, 94%; (d) NaH, 15-crown-5, DMSO, then 5-iodo-2-methylpent-2-ene, 77%; (e) 10 mol% Pd(PPh<sub>3</sub>)<sub>4</sub>, DMSO, 90°C, 60%.



**Figure 3.** Possible transition states **A** and **B** for palladium-catalyzed cyclization of **4**.



**Figure 4.** Most stable conformation of **9a** obtained by MM2 calculation and representative NOE.




**Scheme 2.** Reagents and conditions: (a) TBDMSCl, Et<sub>3</sub>N, 4-DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 74%; (b) LiAlH<sub>4</sub>, THF, 0°C; (c) MsCl, Et<sub>3</sub>N, 4-DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0°C; (d) DBU, toluene, 120°C, 60% over three steps.

would be involved in this cyclization. Namely, the chelation between the palladium and the allyl alcohol formed by Pd(0) oxidative addition of the vinyl epoxide predominately leads to the formation of a *Z*-olefin. If a nucleophilic displacement at the  $\pi$ -allylpalladium intermediate with the anion of the  $\beta$ -ketoester moiety proceeds through a product-like transition state, transition state **A**, which should lead to more stable compound **9** with a pseudoequatorial C-6 unit and a pseudoaxial methyl ester group, favors over transition state **B** bringing into less stable product with the opposite stereochemistry at the quaternary center.

Although the eleven-membered ring was diastereoselectively constructed, the *Z*-geometry of the trisubstituted olefin in **9** has to be converted to an *E* form which is essential for vibsananin F. MM2 calculations of vibsananin F related compounds were performed by using Macro-model<sup>®</sup>, thereby indicating that aldehyde **15** (shown in Scheme 3) with a *Z*-double bond is less stable by 7 kJ mol<sup>-1</sup> than aldehyde **16** with an *E*-double bond. This result encouraged us to attempt isomerization of the *Z*-olefin into the desirable *E*-olefin at a later stage after **9** is converted to the corresponding aldehyde **15**. First, the alcohol **9** was protected with TBDMSCl, followed by reduction of both the carbonyl groups with LiAlH<sub>4</sub> to give rise to the diol **10** without touching the epoxide moiety, which was then mesylated. The resultant dimesylate **10a** was subjected to elimination of the secondary mesylate under standard conditions, giving rise to monomesylate **11** in 60% yield over three steps (Scheme 2).


Subsequent reductive demesylation of **11** to generate a methyl group was troublesome. As shown in Table 1, neither of Zn nor NaBH<sub>3</sub>CN gave the desired compound **12** but a ring expanded product **14** (entry 3 and 5), whereas LiAlH<sub>4</sub> reduction afforded solely an alcohol **13** in good yield (entry 2). After numerous trials, it was pleased to find that reductive demesylation of **11** nicely proceeded with NaBH<sub>4</sub> in aprotic polar solvent<sup>12</sup> to give the desirable product **12**. Particularly, a system of NaBH<sub>4</sub>–DMPU at 55°C reduced selectively the mesylate moiety of **11**, resulting in the formation of **12** in 81% yield.

After deprotection of the silylether in **12** with TBAF, the obtained hydroxyl group was oxidized with Dess–Martin periodinane<sup>13</sup> to yield aldehyde **15** quantitatively. Isomerization of the *Z*-olefin in **15** into the *E*-olefin was effected under radical conditions with



**Scheme 3.** Reagents and conditions: (a) TBAF, THF, 100%; (b) Dess–Martin, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 100%; (c) PhSH, AIBN, benzene, 90°C, 48%; (d) NaBH<sub>4</sub>, CeCl<sub>3</sub>, MeOH, 0°C, 56%.

**Table 1.** Reductive conversion of mesylate **11** to **12**



Entry	Reductive conditions <sup>a</sup>	Product (%)		
		12	13	14
1 <sup>b</sup>	Super hydride, THF, reflux	—	—	—
2	LiAlH <sub>4</sub> , THF, reflux	—	80	—
3	Zn, NaI, HMPA, 110°C	—	—	23
4 <sup>b</sup>	Super hydride, DMSO, 55°C	—	—	—
5	NaBH <sub>3</sub> CN, DMSO, 55°C	—	—	87
6 <sup>c</sup>	NaBH <sub>4</sub> , DMSO, 55°C	69	—	—
7 <sup>d</sup>	NaBH <sub>4</sub> , DMPU, 55°C	81	—	—
8	NaBH <sub>4</sub> , HMPA, 55°C	70	—	—

<sup>a</sup> Excess reagents were used.

<sup>b</sup> No reaction.

<sup>c</sup> **11** (21%) was recovered.

<sup>d</sup> **11** (13%) was recovered.

AIBN and thiophenol<sup>14</sup> to bring into the *E*-olefin **16** in 48% yield. Finally, a conjugated aldehyde group in **16** was reduced by the Luche protocol<sup>15</sup> to afford **1a**.<sup>16</sup> The <sup>1</sup>H NMR of **1a**, however, was not identical with that of natural vibsantin F.

Thus, each epoxide ring of synthetic product **1a** and vibsantin F was reduced with LiAlH<sub>4</sub>, resulting in the preparation of the same diol **17**.<sup>17</sup> <sup>1</sup>H NMR and specific rotation for the both diols derived from synthetic **1a** and natural vibsantin F were identical to each other (synthetic **17**: [α]<sub>D</sub>+33.4°, natural **17**: [α]<sub>D</sub>+32.7°).

In conclusion, we succeeded in the asymmetric synthesis of one (**1a**) of two possible structures for vibsantin F by applying palladium-catalyzed macrocyclization to the vinyl epoxide and the β-ketoester coexisting in a molecule, and thereby could propose the correct absolute configuration of vibsantin F to be **1b** with a 6*R*, 7*S* and 11*S* configuration. Synthesis of the correct structure of vibsantin F is currently ongoing.

### Acknowledgements

We thank Ms. Yasuko Okamoto for measuring MS spectra. This work is supported by a Grant-in Aid for Scientific Research (No. 12480175) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and the Open Research Center Fund from the Promotion and Mutual Aid Corporation for Private School of Japan.

### References

1. Kawazu, K. *Agric. Biol. Chem.* **1980**, *44*, 1367–1372.
2. Fukuyama, K.; Katsube, Y.; Kawazu, K. *J. Chem. Soc., Perkin Trans II* **1980**, 1701–1703.
3. Fukuyama, Y.; Minami, H.; Takaoka, S.; Kodama, M.; Kawazu, K.; Nemoto, H. *Tetrahedron Lett.* **1997**, *38*, 1435–1438.
4. Fukuyama, Y.; Minami, H.; Matsuo, H.; Kitamura, K.; Akizuki, M.; Kubo, M.; Kodama, M. *Chem. Pharm. Bull.* **2002**, *50*, 368–371.
5. Fukuyama, Y.; Minami, H.; Takeuchi, K.; Kodama, M.; Kawazu, K. *Tetrahedron Lett.* **1996**, *37*, 6767–6770.
6. Gao, Y.; Klunder, J. M.; Hanson, R. M.; Masamune, H.; Ko, S. Y.; Sharpless, K. B. *J. Am. Chem. Soc.* **1987**, *109*, 5765–5780.
7. (a) Streiwier, A. *Solvolytic Displacement*; McGraw-Hill: New York, 1962; p. 16; (b) Huckin, S. N.; Weiler, L. J. *Am. Chem. Soc.* **1974**, *96*, 1082–1087.
8. (a) Tsuji, J.; Takahashi, H.; Morikawa, M. *Tetrahedron Lett.* **1965**, *6*, 4387–4388; (b) Kitagawa, Y.; Itoh, A.; Hashimoto, S.; Yamamoto, H.; Nozaki, H. *J. Am. Chem. Soc.* **1977**, *99*, 3864–3867; (c) Trost, B. M.; Verhoeven, T. R. *J. Am. Chem. Soc.* **1980**, *102*, 4730–4743; (d) Schreiber, S. L.; Sammakia, T.; Hulin, B.; Schulte, G. J. *Am. Chem. Soc.* **1986**, *108*, 2106–2108; (e) Trost, B. M.; Verhoeven, T. R. *J. Am. Chem. Soc.* **1980**, *102*, 4743–4763; (f) Trost, B. M.; Molander, G. A. *J. Am. Chem. Soc.* **1981**, *103*, 5969–5972; (g) Tsuji, J.; Kataoka, H.; Kobayashi, Y. *Tetrahedron Lett.* **1981**, *22*, 2575–2578; (h) Consiglio, G.; Waymouth, R. M. *Chem. Rev.* **1981**, *89*, 257–276; (i) Trost, B. M.; Lautens, M. *J. Am. Chem. Soc.* **1987**, *109*, 1469–1478.
9. (a) Büchi, G.; Wuest, H. *Helv. Chim. Acta* **1967**, *50*, 2440; (b) Chhabra, B. R.; Hayano, K.; Ohtsuka, T.; Shirahama, H.; Matsumoto, T. *Chem. Lett.* **1981**, 1703–1706.
10. Williams, R. M.; Maruyama, L. K. *J. Org. Chem.* **1987**, *52*, 4044–4047.
11. The *Z*-geometry of the trisubstituted double bond and the relative configuration of the C-11 quaternary center in **9** were determined on the basis of NOE analysis of the TBDMS derivative **9a** as shown in Figure 4.
12. (a) Bell, H. M.; Vanderslice, S. W.; Spehar, A. *J. Org. Chem.* **1969**, *34*, 3923–3926; (b) Hutchins, R. O.; Hoke, D.; Keogh, J.; Koharski, D. *Tetrahedron Lett.* **1969**, *10*, 3495–3498.
13. (a) Dess, D. B.; Martin, J. C. *J. Org. Chem.* **1983**, *48*, 4155–4196; (b) Ireland, R. E.; Liu, L. *J. Org. Chem.* **1993**, *58*, 2899.
14. Henrick, C. A.; Willy, W. E.; Bum, J. W.; Baer, T. A.; Garcia, B. A.; Mastre, T. A.; Chang, S. M. *J. Org. Chem.* **1975**, *40*, 1–7.
15. Gemal, A. L.; Luche, J. L. *J. Am. Chem. Soc.* **1981**, *103*, 5454–5459.
16. **1a**: [α]<sub>D</sub><sup>20</sup>+46.0° (*c* 0.12, CHCl<sub>3</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.10 (3H, s), 1.31 (3H, s), 1.59 (3H, s), 1.68 (3H, s), 2.54 (1H, dd, *J*=4.9, 12.0 Hz), 2.69 (1H, dd, *J*=3.0, 11.0 Hz), 2.73 (1H, dd, *J*=3.0, 9.6 Hz), 3.96 (1H, d, *J*=12.6 Hz), 4.30 (1H, d, *J*=12.6 Hz), 5.10 (1H, brt, *J*=7.1 Hz), 5.43 (1H, d, *J*=16.2 Hz), 5.53 (1H, ddd, *J*=4.9, 8.5, 16.2 Hz), 5.69 (1H, dd, *J*=3.8, 11.0 Hz). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ 16.4, 17.6, 23.3, 23.4, 23.9, 24.4, 25.7, 39.1, 40.0, 41.5, 43.5, 62.1, 64.2, 66.5, 122.3, 124.4, 131.3, 138.5, 142.5, 145.3. IR (film): 3427, 2964, 1069 cm<sup>-1</sup>. FABMS *m/z* (rel. int.) 327 [M+Na]<sup>+</sup>, 136 (100). HRFABMS *m/z*: 327.2293 [M+Na]<sup>+</sup>; Calcd 327.2300 for C<sub>20</sub>H<sub>32</sub>O<sub>2</sub>Na.
17. **17**: [α]<sub>D</sub><sup>21</sup>+33.4° (*c* 0.6, CHCl<sub>3</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ 1.05 (3H, s), 1.21 (3H, s), 1.60 (3H, s), 1.69 (3H, d, *J*=1.1 Hz), 2.23 (1H, d, *J*=6.0 Hz), 2.23 (1H, d, *J*=6.0 Hz), 3.97 (2H, brs), 5.12 (1H, ddq, *J*=1.1, 7.1, 7.1 Hz), 5.26 (1H, ddd, *J*=6.6, 6.6, 15.9 Hz), 5.30 (1H, d, *J*=15.9 Hz), 5.54 (1H, t, *J*=8.5 Hz).